Serplulimab (3) – Hetronifly®
Squamous cell carcinoma of the oesophagus, PD-L1 with CPS ≥ 5, first-line treatment, in combination with fluoropyrimidine- and platinum-based chemotherapy
Characteristics
| Start date | 01.08.2026 |
|---|---|
| Resolution | 21.01.2027 – active procedure |
| INN | Serplulimab |
| Brand name | Hetronifly® |
| Pharm. company | Accord Healthcare GmbH |
| G-BA Procedure ID | D-1338 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
<< List of all resolutions